Related Experiment Video
Updated: Feb 18, 2026
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Antimicrobial Octapeptin C4 Analogues Active against Cryptococcus Species
Jessica L Chitty1,2, Mark S Butler2, Azzah Suboh2
1Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, Queensland, Australia.
Abstract:
Resistance to antimicrobials is a growing problem in both developed and developing countries. In nations where AIDS is most prevalent, the human fungal pathogen Cryptococcus neoformans is a significant contributor to mortality, and its growing resistance to current antifungals is an ever-expanding threat. We investigated octapeptin C4, from the cationic cyclic lipopeptide class of antimicrobials, as a potential new antifungal. Octapeptin C4 was a potent, selective inhibitor of this fungal pathogen with an MIC of 1.56 μg/ml. Further testing of octapeptin C4 against 40 clinical isolates of C. neoformans var. grubii or neoformans showed an MIC of 1.56 to 3.13 μg/ml, while 20 clinical isolates of C. neoformans var. gattii had an MIC of 0.78 to 12.5 μg/ml. In each case, the MIC values for octapeptin C4 were equivalent to, or better than, current antifungal drugs fluconazole and amphotericin B. The negatively charged polysaccharide capsule of C. neoformans influences the pathogen's sensitivity to octapeptin C4, whereas the degree of melanization had little effect. Testing synthetic octapeptin C4 derivatives provided insight into the structure activity relationships, revealing that the lipophilic amino acid moieties are more important to the activity than the cationic diaminobutyric acid groups. Octapeptins have promising potential for development as anticryptococcal therapeutic agents.
Insights
Octapeptin C4 shows potent antifungal activity against Cryptococcus neoformans, a major cause of mortality in AIDS patients. This novel agent is effective against resistant strains, offering a promising new therapeutic option.
Area of Science:
- Antimicrobial resistance
- Mycology
- Drug discovery
Background:
- Antimicrobial resistance is a global health crisis, particularly impacting opportunistic fungal infections like Cryptococcus neoformans in immunocompromised individuals.
- Cryptococcus neoformans is a significant cause of mortality, especially in regions with high HIV/AIDS prevalence, and exhibits increasing resistance to existing antifungal treatments.
Purpose of the Study:
- To evaluate the antifungal potential of octapeptin C4, a cationic cyclic lipopeptide, against the fungal pathogen Cryptococcus neoformans.
- To determine the minimum inhibitory concentration (MIC) of octapeptin C4 against various clinical isolates of Cryptococcus neoformans and compare its efficacy to current antifungal drugs.
Main Methods:
- Minimum inhibitory concentration (MIC) assays were performed to assess the potency of octapeptin C4 against Cryptococcus neoformans.
- Testing included clinical isolates of C. neoformans var. grubii, neoformans, and gattii, with comparisons made against fluconazole and amphotericin B.
- Structure-activity relationship studies were conducted using synthetic octapeptin C4 derivatives.
Main Results:
- Octapeptin C4 demonstrated potent and selective inhibition of Cryptococcus neoformans with MIC values ranging from 0.78 to 12.5 μg/ml across different varieties.
- Its efficacy was comparable or superior to fluconazole and amphotericin B against clinical isolates.
- The study identified lipophilic amino acid moieties as crucial for octapeptin C4's anticryptococcal activity.
Conclusions:
- Octapeptin C4 exhibits significant potential as a novel therapeutic agent for treating Cryptococcus neoformans infections.
- Its effectiveness against resistant strains highlights its value in addressing the growing challenge of antifungal resistance.
- Further development of octapeptins could lead to new anticryptococcal drugs.
Related Concept Videos
01:23Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
01:28Antimicrobial Effectiveness